Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043766 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Oral PF614 Relative to OxyContin (PF614-102)
A Phase 1 study, sponsored by Ensysce Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT05043766 is a Phase 1 study that has completed, run by Ensysce Biosciences. The registered enrollment target is 84 participants.
The verdict
NCT05043766, a Phase 1 study, has completed, sponsored by Ensysce Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts of the study will be conducted in healthy adult subjects.
Interventions
- DRUG Naltrexone Hydrochloride
- DRUG PF614
- DRUG OxyContin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05043766
The ClinicalTrials.gov registry entry for NCT05043766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensysce Biosciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Naltrexone Hydrochloride is the first listed.
NCT05043766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05043766 about?
NCT05043766 is a clinical study titled "Evaluation of Oral PF614 Relative to OxyContin (PF614-102)". This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B). Both parts of the study will be conducted in healthy adult subjects.
What is the current status of trial NCT05043766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2021-09-08. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT05043766?
The interventions under investigation include: Naltrexone Hydrochloride (DRUG), PF614 (DRUG), OxyContin (DRUG).
Who is sponsoring clinical trial NCT05043766?
This trial is sponsored by Ensysce Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.